{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:36:23Z","timestamp":1772987783059,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Services Research"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess potential Medicare cost savings if Mark Cuban Cost Plus Drug Company (MCCPDC) pricing were applied to antihypertensive medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Setting and Design<\/jats:title>\n                    <jats:p>We conducted a cross\u2010sectional analysis comparing Medicare Part D spending with MCCPDC pricing for selected antihypertensive drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Analytic Sample<\/jats:title>\n                    <jats:p>Eighty\u2010seven antihypertensive medications were compared between Medicare Part D and MCCPDC. Volume\u2010adjusted expenditure estimates were calculated under three scenarios: (1) applying MCCPDC prices to all medications, (2) applying MCCPDC prices only to drugs priced lower than Medicare, and (3) applying MCCPDC prices to guideline\u2010recommended first\u2010line therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Principal Findings<\/jats:title>\n                    <jats:p>In 2022, Medicare spent $4.9 billion on the included medications. Of these, 39 of the 30\u2010count and 58 of the 90\u2010count medications showed cost savings under MCCPDC pricing. Estimated savings totaled $670.1 million (30\u2010count) and $1.4 billion (90\u2010count). Among 47 first\u2010line agents, MCCPDC pricing produced estimated savings of $222.6 million (30\u2010count) and $584.1 million (90\u2010count). The average 90\u2010count price reduction was 23.2% overall and 21.1% among first\u2010line therapies, with several agents showing substantial price advantages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adopting MCCPDC pricing could reduce Medicare costs for antihypertensive drugs, especially through 90\u2010count supplies and first\u2010line therapies. Targeted implementation\u2014focusing on medications with clear cost and clinical advantages\u2014may yield meaningful savings. These results support broader policy efforts to incorporate transparent, value\u2010based drug pricing models into Medicare.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1475-6773.70045","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:02:46Z","timestamp":1758294166000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disrupting Drug Costs: The Role of Cost\u2010Plus Pricing in Reducing Medicare Spending on Hypertension Treatments"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-0406","authenticated-orcid":false,"given":"Jacob","family":"Duncan","sequence":"first","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew V.","family":"Tran","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Witt","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annes","family":"Elfar","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rashid","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"},{"name":"Department of Psychiatry and Behavioral Sciences Oklahoma State University Center for Health Sciences Tulsa Oklahoma USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxae104"},{"key":"e_1_2_10_3_1","unstructured":"Center for Medicare Advocacy \u201cMedicare Enrollment Numbers \u201d2023 https:\/\/medicareadvocacy.org\/medicare\u2010enrollment\u2010numbers\/."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000002331"},{"key":"e_1_2_10_5_1","unstructured":"KFF \u201cThe Facts About Medicare Spending \u201d2023 https:\/\/www.kff.org\/interactive\/the\u2010facts\u2010about\u2010medicare\u2010spending\/."},{"key":"e_1_2_10_6_1","unstructured":"\u201cMission of Mark Cuban Cost Plus Drugs \u201d2023 https:\/\/costplusdrugs.com\/mission\/."},{"key":"e_1_2_10_7_1","unstructured":"\u201cMark Cuban Cost Plus Drug Company \u201dhttps:\/\/www.markcubancostplusdrugcompany.com\/."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00079"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003083"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008731"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2019.05.002"},{"key":"e_1_2_10_12_1","unstructured":"CDC \u201cFacts About Hypertension \u201dCenters for Disease Control and Prevention https:\/\/www.cdc.gov\/bloodpressure\/facts.htm."},{"key":"e_1_2_10_13_1","unstructured":"\u201cCenters for Medicare and Medicaid Services Data \u201dhttps:\/\/data.cms.gov\/provider\u2010summary\u2010by\u2010type\u2010of\u2010service\/medicare\u2010part\u2010d\u2010prescribers\/medicare\u2010part\u2010d\u2010prescribers\u2010by\u2010provider\u2010and\u2010drug."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0756"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2017.88"},{"key":"e_1_2_10_16_1","unstructured":"\u201cAvailable Medications \u201dhttps:\/\/costplusdrugs.com\/medications\/categories\/high\u2010blood\u2010pressure\/."},{"key":"e_1_2_10_17_1","unstructured":"\u201cChapter\u00a05: Collecting Data \u201dhttps:\/\/training.cochrane.org\/handbook\/current\/chapter\u201005."},{"key":"e_1_2_10_18_1","unstructured":"\u201cCenters for Medicare and Medicaid Services Data \u201dhttps:\/\/data.cms.gov\/resources\/medicare\u2010part\u2010d\u2010spending\u2010by\u2010drug\u2010data\u2010dictionary."},{"key":"e_1_2_10_19_1","unstructured":"\u201cMark Cuban's Cost Plus Partners With Telehealth Firm to Offer Employers Obesity Care Drugs \u201dReuters https:\/\/www.reuters.com\/business\/healthcare\u2010pharmaceuticals\/mark\u2010cubans\u2010cost\u2010plus\u2010partners\u2010with\u2010telehealth\u2010firm\u2010offer\u2010employers\u2010obesity\u2010care\u20102025\u201006\u201017\/."},{"key":"e_1_2_10_20_1","unstructured":"E.Li \u201cPenn Medicine Partners With Mark Cuban's Cost Plus Drugs to Increase Medication Supply Reduce Costs \u201dhttps:\/\/www.thedp.com\/article\/2025\/01\/penn\u2010medicine\u2010partners\u2010mark\u2010cuban\u2010prescription\u2010drug\u2010efficiency."},{"key":"e_1_2_10_21_1","unstructured":"R.Pifer \u201cCommunity Health Systems to Buy Drugs From Mark Cuban Cost Plus \u201dHealthcare Dive2024 https:\/\/www.healthcaredive.com\/news\/community\u2010health\u2010systems\u2010mark\u2010cuban\u2010cost\u2010plus\u2010deal\/709712\/."},{"key":"e_1_2_10_22_1","unstructured":"F.Kansteiner \u201cHHS DARPA Link Up With Rutgers Cost Plus Drugs and Others in Initiative to Rethink US Drug Production \u201dFierce Pharma 2025 https:\/\/www.fiercepharma.com\/manufacturing\/hhs\u2010darpa\u2010link\u2010rutgers\u2010cost\u2010plus\u2010drugs\u2010and\u2010others\u2010under\u2010initiative\u2010overhaul\u2010us\u2010drugothers."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0483"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-018-0156-8"},{"key":"e_1_2_10_25_1","unstructured":"Center for Drug Evaluation Research \u201cGeneric Drugs. U.S. Food and Drug Administration \u201d2023 https:\/\/www.fda.gov\/drugs\/buying\u2010using\u2010medicine\u2010safely\/generic\u2010drugs?utm_source=cs%20blog&utm_campaign=cs%20blog%20post&utm_medium=referral&utm_content=generic\u2010vs\u2010brand\u2010name\u2010drugs\u2010whats\u2010the\u2010difference."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9010001"},{"key":"e_1_2_10_27_1","unstructured":"NASHP \u201cPrescription Drug Pricing Transparency Law Comparison Chart \u201d2021 https:\/\/nashp.org\/prescription\u2010drug\u2010pricing\u2010transparency\u2010law\u2010comparison\u2010chart\/."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5202-155"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/00469580231155988"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08108-4"}],"container-title":["Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1475-6773.70045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1475-6773.70045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1475-6773.70045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:06:54Z","timestamp":1772968014000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1475-6773.70045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/1475-6773.70045"],"URL":"https:\/\/doi.org\/10.1111\/1475-6773.70045","archive":["Portico"],"relation":{},"ISSN":["0017-9124","1475-6773"],"issn-type":[{"value":"0017-9124","type":"print"},{"value":"1475-6773","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70045"}}